Glycemic Control: Dapagliflozin vs Empagliflozin
For glucose control specifically, empagliflozin demonstrates slightly superior HbA1c reduction compared to dapagliflozin, though the clinical difference is modest and both agents are highly effective.
Evidence-Based Comparison
Glycemic Efficacy
The most recent head-to-head evidence shows empagliflozin achieves marginally better glucose lowering:
- Empagliflozin 25 mg reduces HbA1c by approximately -1.7% 1
- Dapagliflozin 10 mg reduces HbA1c by approximately -1.2% 1
- This difference was statistically significant (p=0.002) 1
A 3-year retrospective study confirmed no significant difference in long-term glycemic control between the two agents, with both achieving sustained HbA1c reductions and similar proportions of patients reaching HbA1c targets <7.0% 2. However, empagliflozin showed superior fasting blood glucose reduction (-75.6 mg/dL vs -63.5 mg/dL, p=0.001) 1.
A 2026 network meta-analysis ranked SGLT2 inhibitors by efficacy: canagliflozin 300 mg ranked highest for HbA1c reduction, followed by canagliflozin 100 mg and empagliflozin 25 mg, all of which were superior to bexagliflozin 3. Empagliflozin and dapagliflozin showed comparable efficacy to most other SGLT2 inhibitors.
Guideline Context
The 2025 ADA Standards of Care classify both agents as having "intermediate to high" glucose-lowering efficacy and note that both canagliflozin, empagliflozin, and dapagliflozin provide cardiovascular and renal benefits 4. The guidelines emphasize that SGLT2 inhibitors should be selected based on comorbidities (heart failure, CKD, ASCVD) rather than glucose-lowering potency alone.
Additional Metabolic Effects
Both agents provide similar benefits beyond glucose control:
- Weight loss: Empagliflozin -2.9 kg vs dapagliflozin -1.7 kg at 12 weeks (not significantly different, p=0.032) 1
- Blood pressure reduction: Both reduce systolic and diastolic BP comparably 2
- Lipid effects: Both reduce triglycerides and ALT levels 2, 5
Empagliflozin showed superior reduction in microalbuminuria and ALT levels compared to dapagliflozin in one real-world study 5.
Safety Considerations
Urogenital infections are the primary differentiating safety concern:
- Dapagliflozin has higher rates of urinary tract infections (7.08% vs 2.34%, p=0.003) and genital infections (8.66% vs 3.1%, p=0.005) compared to empagliflozin 1
- A 2026 target trial emulation confirmed empagliflozin had slightly lower absolute risks of genital tract infections (2.2% vs 2.0%) and phimosis (1.0% vs 0.8%), though differences were small 6
- Both agents have similar rates of DKA, volume depletion, and Fournier gangrene (rare) 4
Clinical Algorithm for Selection
Choose empagliflozin 25 mg when:
- Maximizing HbA1c reduction is the priority
- Patient has history of recurrent urogenital infections
- Fasting glucose is particularly elevated
Choose dapagliflozin 10 mg when:
- Patient has chronic kidney disease (extensively studied in DAPA-CKD trial with eGFR as low as 25 mL/min/1.73 m²) 7
- Cost or formulary considerations favor dapagliflozin
- Long-term outcomes are equivalent priority to immediate glucose control
Either agent is appropriate when:
- Cardiovascular or renal protection is the primary goal (both equally effective) 8, 9
- Patient needs moderate glucose lowering with weight loss
- No history of urogenital infections
Important Caveats
- Glucose-lowering effect diminishes below eGFR 45 mL/min/1.73 m², though cardiovascular and renal benefits persist until dialysis 4
- Both agents require adequate volume status; monitor for hypotension in elderly patients or those on diuretics 4, 7
- Discontinue 3-4 days before surgery to reduce DKA risk 4
- The absolute difference in HbA1c reduction (0.5%) between these agents is clinically modest—comorbidities should drive selection more than glucose-lowering potency alone